Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

By M. Overman, R. McDermott, J. Leach, S. Lonardi, H. Lenz, M. Morse, J. Desai, A. Hill, M. Axelson, R. Moss and 6 more. The Lancet Oncology, 2017

2,424 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/ec3b980a8461bef5876ab996e8ad0d0bba2b00bf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “In the United States, these therapies are approved for unresectable colorec‐ tal cancer with MMR deficiency [202, 226].”
Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “We have attempted to infer the rates of acquired resistance based upon available duration of response data among different tumor types (Antonia et al., 2019; Armand et al., 2018; Balar et al., 2018; Burtness et al., 2019; Chen et al., 2019a; Cohen et al., 2019; Fehrenbacher et al., 2018; Fradet et a”
Combination of CTLA-4 and PD-1 blockers for treatment of cancer (2019, background): “In an open-label phase 2 study, blockade of PD-1 receptors with nivolumab recorded an ORR of 31%, disease control rate of 69% and 12-month OS rate of 73% [101].”
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, background): “The ORR and duration of response to nivolumab in the CheckMate-142 trial lead to its accelerated approval on 1 August 2017 for this group of patients [34] (Category 2A).”
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. (2018, neutral): “1 (8-20) 12 (40) 3 (50) Not reached (2-93) Not reached (2-48) 11 (37) 4 (67) GI 27 (23) 4 (3) 9.”
Comprehensive review of targeted therapy for colorectal cancer (2020, background): “The predictive role of PD-L1 expression in CRC is considered to be limited because in pMMR CRC, no obvious trend was observed between PD-L1 expression levels and drug efficacy.(382,387) A high mutational burden correlates with elevated levels of neoantigens.”
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 (2019, neutral): “Complete response 2 (3) 0 to 11 5 (8) 3 to 18”